Amaryl 3mg 15pcs

Indications

Patients with non-insulin-dependent diabetes mellitus (type 2 diabetes) whose hyperglycemia cannot be controlled by diet, exercise, and weight loss are prescribed glimepiride as a supplement to diet to lower blood glucose. In patients whose hyperglycemia cannot be controlled by diet and exercise or in conjunction with an oral hypoglycaemic agent, glimepiride is also indicated for use in combination with insulin to lower blood glucose levels.

Pharmacology

Glimepiride stimulates the insulin release from pancreatic ?-cells and reduces glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.

Dosage

• In theory, the desired blood sugar level determines the Glimepiride dosage. The smallest Glimepiride dosage necessary to achieve the desired metabolic control must be used. Based on the findings of routine checks of blood and urine glucose levels, the initial and maintenance doses are determined. Monitoring the amount of glucose in the blood and urine also helps to identify treatment failure, either primary or secondary.
• Initial dose and dose titration: The initial dose is typically 1 mg once daily, but this can be increased as needed. Any increase should be gradual, i.e., carried out in steps over intervals of one to two weeks, and can be based on routine blood sugar monitoring. For example: 1 mg, 2 mg, 3 mg, 4 mg, and 6 mg.
• Dosage in patients with well-controlled diabetes: Patients with well-controlled diabetes typically receive a dose ranging from 1 to 4 mg per day.
  Dose distribution: Taking into account the patient’s current lifestyle, the doctor determines the timing and distribution of doses. Typically, one dose per day is sufficient. If no substantial breakfast is consumed right away before the first main meal, this should be taken. It’s crucial to avoid skipping meals after taking the medication.
• Secondary dosage adjustment: As diabetes, control improves, sensitivity to insulin rises; as a result, as treatment progresses, Glimepiride requirements may decrease. The prompt dose reduction or discontinuation of Glimepiride therapy must be taken into consideration to prevent hypoglycemia. Every time the patient’s weight, lifestyle, or other factors change and make them more susceptible to hypo- or hyperglycemia, a dose adjustment must be taken into account.
• Switching from other oral antidiabetics to glimepiride: Glimepiride and other oral blood sugar-lowering medications do not have a precise dosage relationship. The initial daily dose of Glimepiride is 1 mg when replacing other similar medications; this holds true even when switching from the maximum dosage of other oral blood sugar-lowering medications. Any dose increase must follow the instructions in “initial dose and dose titration” above. The effectiveness and duration of the previous blood sugar-lowering medication must be taken into account. To prevent additive effects that would raise the risk of hypoglycemia, treatment may need to be stopped.

Administration

• The Amaryl tablet needs to be taken whole, without chewing, and with enough liquid (roughly a half glass).
• Take it right before or alongside your morning meal (usually breakfast). Don’t skip meals.

Interaction

Anabolic steroids, male sex hormones, chloramphenicol, coumarin derivatives, Fluoxetine, MAO inhibitors, Miconazole, Para-aminosalicylic acid, Pentoxifylline (high dose parenteral), Phenylbutazone, Oxyphenbutazone, quinolones, salicylates, sulphonamides, tetracyclines, and beta blockers may all potentiate the With Acetazolamide, barbiturates, corticosteroids, Diazoxide, diuretics, epinephrine, and other sympathomimetic agents, laxatives, estrogens and progestogens, phenothiazines, phenytoin, Rifampicin, and thyroid hormones, the blood sugar-lowering effect may be lessened. Clonidine and Reserpine are H2 -receptor antagonists that may either strengthen or weaken the blood sugar-lowering effect. Acute and long-term alcohol use may unexpectedly strengthen or weaken Glimepiride’s ability to lower blood sugar.

Contraindications

Glimepiride is not suitable for the treatment of insulin-dependent (type-I) diabetes mellitus, or of diabetic pre-coma or coma. Glimepiride must not be used in patients hypersensitive to Glimepiride or other sulphonylureas.

Side Effects

Hypoglycaemia, temporary visual impairment, nausea, vomiting, diarrhea, abdominal pain, urticaria & fall in blood pressure.

Pregnancy & Lactation

Glimepiride must not be taken during pregnancy; a changeover to Insulin is necessary. Patients planning a pregnancy must inform their physician, and should be shifted to Insulin. Lactation: Ingestion of Glimepiride with breast milk may harm the child. Therefore, Glimepiride must not be taken by lactating women. Either a changeover or a complete discontinuation of breastfeeding is necessary.

Precautions & Warnings

• The risk of hypoglycemia may be increased during the first few weeks of treatment, necessitating careful monitoring.
• The dosage of Glimepiride may need to be changed if this risk is present.
• Use in Special Populations Pediatric use: Safety and efficacy in pediatric patients have not been established. Hypoglycemia can almost always be quickly controlled by immediate intake of carbohydrates (glucose or sugar, for example, sugar-sweetened fruit juice or sugar-sweetened tea).
• Geriatric use: Overall, there were no differences in safety or effectiveness between elderly and adult subjects, but it is possible that some older people may be more sensitive. The risk of toxic reactions to this medication may be higher in patients with impaired renal function because the drug is known to be substantially excreted by the kidney. Renal function should be carefully considered when choosing a dose because elderly patients are more likely to have decreased renal function. It may also be helpful to monitor renal function.
• Use in renal insufficiency: Patients with NIDDM who have kidney disease may receive a starting dose of 1 mg of glimepiride, and the dose may be adjusted based on fasting blood glucose levels.
• Use in hepatic insufficiency: Hepatic insufficiency patients were not the subjects of any studies. Negative effects include hypoglycemia. Dizziness, asthenia, headache, and nausea are adverse events besides hypoglycemia.
• Effects of Overdose Overdosing, whether accidental or intentional, can result in severe, protracted hypoglycemia that can be fatal.
• Glimepiride overdose cases must be reported right away to a doctor. If a doctor has not already begun treatment, the patient must take sugar right away, preferably glucose, at the first sign of hypoglycemia.

Storage Conditions

Do not store at temperatures above 30?C. Keep out of the reach of youngsters and away from light.